← Leaderboards
Sharon Rosenzweig-Lipson
Agenebio, Inc.
$9,435,769
Attributed
$9,647,680
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2012–23$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$9,647,680 · 5
By mechanism
U01$4,774,324 · 2
R44$3,229,045 · 1
UH3$992,883 · 1
UH2$651,428 · 1
Top collaborators
- Michela Gallagher1 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposProgramsS DiseaseCoupledRattusMild Cognitive ImpairmentPreclinical StudyGamma-Aminobutyric AcidReceptorNeuronsIn VivoHippocampus (Brain)MemoryMemory LossDosePerformanceLeadIn VitroPharmaceutical ChemistryAntiepileptic AgentsAge-Associated Memory ImpairmentPathologyPatient PopulationMedial
Grant awards (18)
Preclinical and early clinical development of a GABA-A a5 PAM$1,100,000
U01 · FY2023 · AG · contact PI
Preclinical and early clinical development of a GABA-A a5 PAM$275,000
U01 · FY2023 · AG · contact PI
Preclinical and early clinical development of a GABA-A a5 PAM$1,100,000
U01 · FY2022 · AG · contact PI
Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD$625,713
R44 · FY2021 · AG · contact PI
Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD$235,374
R44 · FY2021 · AG · contact PI
Discovery/Development of GABA-A ÃÂñ5 Positive Allosteric Modulators for Treatment of MCI due to AD$1
UH3 · FY2021 · NS · contact PI
Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD$1,249,115
R44 · FY2020 · AG · contact PI
Structurally Diverse GABA-A ÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂñ5 Positive Allosteric Modulators for Treatment of MCI due to AD$1,118,843
R44 · FY2019 · AG · contact PI
Discovery/Development of GABA-A α5 Positive Allosteric Modulators for Treatment of MCI due to AD$206,281
UH3 · FY2019 · NS · contact PI
Discovery/Development of GABA-A ÃÂñ5 Positive Allosteric Modulators for Treatment of MCI due to AD$134,923
UH3 · FY2019 · NS · contact PI
Discovery/Development of GABA-A α5 Positive Allosteric Modulators for Treatment of MCI due to AD$651,678
UH3 · FY2018 · NS · contact PI
Discovery/Development of GABA-A α5 Positive Allosteric Modulators for Treatment of MCI due to AD$651,428
UH2 · FY2017 · NS · contact PI
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$424,363
U01 · FY2016 · AG · contact PI
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$250,000
U01 · FY2016 · AG · contact PI
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$376,259
U01 · FY2015 · AG · contact PI
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$424,363
U01 · FY2014 · AG · contact PI
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$400,517
U01 · FY2013 · AG · contact PI
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$423,822
U01 · FY2012 · AG · contact PI